Skip to main content
HR 5573 114th Congress House Health Drug safety, medical device, and laboratory regulation Licensing and registrations Marketing and advertising

PRICED Act

Introduced: June 23, 2016 Introduced by: Schakowsky, Janice D. Democratic · Illinois See on congress.gov
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 23, 2016
Referred to the House Committee on Energy and Commerce.
Jun 23, 2016
Introduced in House
 Plain-English summary Congressional Research Service

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.

This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
What's happening now June 23, 2016

Referred to the House Committee on Energy and Commerce.

 Committees of jurisdiction 1